Exact Therapeutics AS (EXTX) - Cash Flow Conversion Efficiency

Latest as of December 2024: -0.697x

Based on the latest financial reports, Exact Therapeutics AS (EXTX) has a cash flow conversion efficiency ratio of -0.697x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-80.55 Million ≈ $-8.48 Million USD) by net assets (Nkr115.55 Million ≈ $12.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See EXTX net asset quality score to measure how much of total assets are equity-financed.

Exact Therapeutics AS - Cash Flow Conversion Efficiency Trend (2017–2024)

This chart illustrates how Exact Therapeutics AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore EXTX operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.

Exact Therapeutics AS Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Exact Therapeutics AS ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Fairchild Gold Corp V:FAIR	-0.117x
Above Food Ingredients Inc. Common Stock NASDAQ:ABVE	0.000x
Supreme Engineering Limited NSE:SUPREMEENG	-0.011x
Instituto Rosenbusch S.A. BA:ROSE	-1.542x
Novakand Pharma AB (publ) ST:LARK	-0.029x
Bio Green Med Solution, Inc. NASDAQ:BGMS	-0.005x
Allergy Therapeutics LSE:AGY	0.748x
Hansa Investment Company Ltd LSE:HANA	0.020x

Annual Cash Flow Conversion Efficiency for Exact Therapeutics AS (2017–2024)

The table below shows the annual cash flow conversion efficiency of Exact Therapeutics AS from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Exact Therapeutics AS (EXTX) total market value.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Nkr115.55 Million ≈ $12.16 Million	Nkr-80.55 Million ≈ $-8.48 Million	-0.697x	+29.02%
2023-12-31	Nkr45.10 Million ≈ $4.75 Million	Nkr-44.30 Million ≈ $-4.66 Million	-0.982x	-88.90%
2022-12-31	Nkr65.11 Million ≈ $6.85 Million	Nkr-33.85 Million ≈ $-3.56 Million	-0.520x	+0.24%
2021-12-31	Nkr105.74 Million ≈ $11.13 Million	Nkr-55.11 Million ≈ $-5.80 Million	-0.521x	-220.16%
2020-12-31	Nkr159.65 Million ≈ $16.80 Million	Nkr-25.99 Million ≈ $-2.73 Million	-0.163x	+44.84%
2019-12-31	Nkr42.24 Million ≈ $4.44 Million	Nkr-12.46 Million ≈ $-1.31 Million	-0.295x	-35.10%
2018-12-31	Nkr57.06 Million ≈ $6.00 Million	Nkr-12.46 Million ≈ $-1.31 Million	-0.218x	+85.37%
2017-12-31	Nkr8.35 Million ≈ $878.27K	Nkr-12.46 Million ≈ $-1.31 Million	-1.493x	--

About Exact Therapeutics AS

OL:EXTX Norway Biotechnology

Market Cap

$4.86 Million

Nkr46.18 Million NOK

Market Cap Rank

#28643 Global

#257 in Norway

Share Price

Nkr0.73

Change (1 day)

+0.69%

52-Week Range

Nkr0.65 - Nkr3.00

All Time High

Nkr40.90